{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:01:28Z","timestamp":1790532088264,"version":"4.1.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Matrix Biology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.matbio.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T06:30:43Z","timestamp":1523514643000},"page":"435-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":399,"special_numbering":"C","title":["Liver fibrosis: Direct antifibrotic agents and targeted therapies"],"prefix":"10.1016","volume":"68-69","author":[{"given":"Detlef","family":"Schuppan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ashfaq-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Ook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9615","key":"10.1016\/j.matbio.2018.04.006_bb0005","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"issue":"167","key":"10.1016\/j.matbio.2018.04.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004700","article-title":"Therapy for fibrotic diseases: nearing the starting line","volume":"5","author":"Friedman","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0015","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.27720","article-title":"Strategies and endpoints of antifibrotic drug trials: summary and recommendations from the AASLD emerging trends conference, Chicago, June 2014","volume":"62","author":"Torok","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0035-1550055","article-title":"Antifibrotic therapies in the liver","volume":"35","author":"Mehal","year":"2015","journal-title":"Semin. Liver Dis."},{"issue":"1 Suppl","key":"10.1016\/j.matbio.2018.04.006_bb0030","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0040","first-page":"96","article-title":"Fibrosis\u2014a common pathway to organ injury and failure","volume":"373","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2008-1040452","article-title":"Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins","volume":"10","author":"Schuppan","year":"1990","journal-title":"Semin. Liver Dis."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2001-17556","article-title":"Matrix as a modulator of hepatic fibrogenesis","volume":"21","author":"Schuppan","year":"2001","journal-title":"Semin. Liver Dis."},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0055","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","article-title":"The good and the bad collagens of fibrosis - their role in signaling and organ function","volume":"121","author":"Karsdal","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s004180050126","article-title":"Heterogeneity of liver cells expressing procollagen types I and IV in vivo","volume":"107","author":"Herbst","year":"1997","journal-title":"Histochem. Cell Biol."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0070","doi-asserted-by":"crossref","first-page":"G1147","DOI":"10.1152\/ajpgi.00032.2007","article-title":"Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis","volume":"293","author":"Georges","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0075","doi-asserted-by":"crossref","first-page":"G110","DOI":"10.1152\/ajpgi.00412.2010","article-title":"Hepatic stellate cells require a stiff environment for myofibroblastic differentiation","volume":"301","author":"Olsen","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9440(10)65299-6","article-title":"Oval cell numbers in human chronic liver diseases are directly related to disease severity","volume":"154","author":"Lowes","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2007.05.012","article-title":"Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction","volume":"133","author":"Richardson","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0090","first-page":"1221","article-title":"Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease","volume":"139","author":"Milani","year":"1991","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0095","first-page":"785","article-title":"Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis","volume":"148","author":"Pinzani","year":"1996","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0100","first-page":"3331","article-title":"Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans","volume":"118","author":"Omenetti","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"9865","key":"10.1016\/j.matbio.2018.04.006_bb0105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.matbio.2018.04.006_bb0115","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/cncr.29528","article-title":"Impact of hepatitis C virus eradication on hepatocellular carcinogenesis","volume":"121","author":"Li","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0120","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0125","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","article-title":"Sterile inflammation in the liver","volume":"143","author":"Kubes","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"46","key":"10.1016\/j.matbio.2018.04.006_bb0135","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2018.04.006_bb0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ebiom.2018.01.028","article-title":"IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal","volume":"29","author":"Weng","year":"2018","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0145","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.22950","article-title":"Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis","volume":"50","author":"Karlmark","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0155","doi-asserted-by":"crossref","first-page":"G323","DOI":"10.1152\/ajpgi.00394.2009","article-title":"Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis","volume":"298","author":"Popov","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0160","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0165","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hep.26783","article-title":"Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice","volume":"59","author":"Baeck","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.matbio.2018.04.006_bb0170","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0168-8278(12)60008-7","article-title":"Anti-fibrotic therapy: lost in translation?","volume":"56","author":"Schuppan","year":"2012","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0175","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/hep.23123","article-title":"Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies","volume":"50","author":"Popov","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0180","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1053\/j.gastro.2011.01.040","article-title":"Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice","volume":"140","author":"Popov","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0185","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2005.06.025","article-title":"Mdr2 (Abcb4)\u2212\/\u2212 mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes","volume":"43","author":"Popov","year":"2005","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0190","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2015.11.002","article-title":"Liver bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis","volume":"64","author":"Eguchi","year":"2016","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0195","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd4592","article-title":"Dissecting fibrosis: therapeutic insights from the small-molecule toolbox","volume":"14","author":"Nanthakumar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0036-1571295","article-title":"Antifibrotic therapies: where are we now?","volume":"36","author":"Yoon","year":"2016","journal-title":"Semin. Liver Dis."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0205","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","article-title":"Pharmacotherapy for NASH: current and emerging","volume":"68","author":"Konerman","year":"2018","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0210","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/hep.27936","article-title":"Specific hepatic delivery of procollagen alpha1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis","volume":"62","author":"Jimenez Calvente","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.matbio.2018.04.006_bb0215","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.matbio.2017.11.002","article-title":"Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation","volume":"66","author":"Molokanova","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2016.12.006","article-title":"SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles","volume":"248","author":"Leber","year":"2017","journal-title":"J. Control. Release"},{"issue":"18","key":"10.1016\/j.matbio.2018.04.006_bb0225","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/adhm.201500826","article-title":"In vivo gene-silencing in fibrotic liver by siRNA-loaded cationic nanohydrogel particles","volume":"4","author":"Kaps","year":"2015","journal-title":"Adv. Healthc. Mater."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0235","series-title":"Clinical Phase 1b\/2 Study Results for Safety, Pharmacokinetics, and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis","first-page":"237A","author":"Lawitz E","year":"2017"},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0240","doi-asserted-by":"crossref","first-page":"G605","DOI":"10.1152\/ajpgi.00222.2012","article-title":"Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury","volume":"304","author":"Perepelyuk","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"7","key":"10.1016\/j.matbio.2018.04.006_bb0245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0945-053X(98)90012-9","article-title":"Lysyl oxidase: properties, regulation and multiple functions in biology","volume":"16","author":"Smith-Mungo","year":"1998","journal-title":"Matrix Biol."},{"issue":"52","key":"10.1016\/j.matbio.2018.04.006_bb0250","doi-asserted-by":"crossref","first-page":"42848","DOI":"10.1074\/jbc.M506832200","article-title":"The pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers","volume":"280","author":"Thomassin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0255","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbadis.2005.02.007","article-title":"The type of collagen cross-link determines the reversibility of experimental skin fibrosis","volume":"1740","author":"van der Slot-Verhoeven","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0260","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbm.a.10021","article-title":"Enhancing mechanical properties of tissue-engineered constructs via lysyl oxidase crosslinking activity","volume":"66","author":"Elbjeirami","year":"2003","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02368184","article-title":"Mechanisms and dynamics of mechanical strengthening in ligament-equivalent fibroblast-populated collagen matrices","volume":"21","author":"Huang","year":"1993","journal-title":"Ann. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0270","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1073\/pnas.75.6.2945","article-title":"Biochemical and immunochemical study of lysyl oxidase in experimental hepatic fibrosis in the rat","volume":"75","author":"Siegel","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2018.04.006_bb0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/189071a0","article-title":"Inhibition of experimental cirrhosis by carbon tetrachloride following treatment with aminoacetonitrile","volume":"189","author":"Fiume","year":"1961","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0280","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1096\/fj.14-268425","article-title":"Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice","volume":"30","author":"Liu","year":"2016","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.matbio.2018.04.006_bb0285","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","article-title":"Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal","volume":"66","author":"Ikenaga","year":"2017","journal-title":"Gut"},{"issue":"46","key":"10.1016\/j.matbio.2018.04.006_bb0290","doi-asserted-by":"crossref","first-page":"36341","DOI":"10.1074\/jbc.M003362200","article-title":"Lysyl oxidase activates the transcription activity of human collagene III promoter. Possible involvement of Ku antigen","volume":"275","author":"Giampuzzi","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"35","key":"10.1016\/j.matbio.2018.04.006_bb0295","doi-asserted-by":"crossref","first-page":"24103","DOI":"10.1074\/jbc.M709897200","article-title":"Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells","volume":"283","author":"Lucero","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"49","key":"10.1016\/j.matbio.2018.04.006_bb0300","doi-asserted-by":"crossref","first-page":"34229","DOI":"10.1074\/jbc.M803142200","article-title":"Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity","volume":"283","author":"Atsawasuwan","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.matbio.2018.04.006_bb0305","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2018.04.006_bb0310","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","author":"Loomba","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","article-title":"Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial","volume":"5","author":"Raghu","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.matbio.2018.04.006_bb0320","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/pro.2162","article-title":"Regulation of the activities of the mammalian transglutaminase family of enzymes","volume":"21","author":"Klock","year":"2012","journal-title":"Protein Sci."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0325","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0021-9258(19)75743-3","article-title":"Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen","volume":"262","author":"Bowness","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0330","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0049-3848(89)90094-7","article-title":"Transglutaminase-catalysed cross-linking: a potential mechanism for the interaction of fibrinogen, low density lipoprotein and arterial type III procollagen","volume":"54","author":"Bowness","year":"1989","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0335","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2353\/ajpath.2008.080025","article-title":"Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration","volume":"173","author":"Shweke","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"Pt 1","key":"10.1016\/j.matbio.2018.04.006_bb0340","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1042\/bj3240311","article-title":"Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC)","volume":"324","author":"Rosenblatt","year":"1997","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0345","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","article-title":"Celiac disease: from pathogenesis to novel therapies","volume":"137","author":"Schuppan","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0350","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0168-8278(01)00135-0","article-title":"Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis","volume":"35","author":"Grenard","year":"2001","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.matbio.2018.04.006_bb0355","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1053\/j.gastro.2004.03.009","article-title":"Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking","volume":"126","author":"Issa","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0360","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000255966","article-title":"Transglutaminase 2 deficiency decreases plaque fibrosis and increases plaque inflammation in apolipoprotein-E-deficient mice","volume":"47","author":"Van Herck","year":"2010","journal-title":"J. Vasc. Res."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.150","article-title":"Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death","volume":"7","author":"Tatsukawa","year":"2016","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0370","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chembiol.2015.08.013","article-title":"Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions","volume":"22","author":"Badarau","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0375","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9719","key":"10.1016\/j.matbio.2018.04.006_bb0380","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.matbio.2018.04.006_bb0385","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2017.02.019","article-title":"Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (the MICA-study)","volume":"259","author":"Waldmann","year":"2017","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1016\/j.matbio.2018.04.006_bb0390","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0395","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"issue":"21","key":"10.1016\/j.matbio.2018.04.006_bb0405","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1073\/pnas.1406228111","article-title":"RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice","volume":"111","author":"Yasuda","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.matbio.2018.04.006_bb0410","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0415","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/nat.2016.0623","article-title":"Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys","volume":"26","author":"Yu","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.matbio.2018.04.006_bb0420","article-title":"Using antisense technology to develop a novel therapy for alpha-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease","volume":"2","author":"Guo","year":"2014","journal-title":"Rare Dis."},{"key":"10.1016\/j.matbio.2018.04.006_bb0425","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0430","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0435","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2011.04.008","article-title":"Targeted therapy of liver fibrosis\/cirrhosis and its complications","volume":"55","author":"Poelstra","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0440","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jconrel.2017.11.029","article-title":"Pharmacokinetics of a sustained release formulation of PDGFbeta-receptor directed carrier proteins to target the fibrotic liver","volume":"269","author":"van Dijk","year":"2018","journal-title":"J. Control. Release"},{"issue":"17","key":"10.1016\/j.matbio.2018.04.006_bb0445","doi-asserted-by":"crossref","first-page":"12743","DOI":"10.1074\/jbc.275.17.12743","article-title":"Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor","volume":"275","author":"Beljaars","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0450","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.23419","article-title":"Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats","volume":"51","author":"Moreno","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0455","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSC-specific inhibition of rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects","volume":"57","author":"Klein","year":"2012","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056442","article-title":"Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury","volume":"8","author":"van Beuge","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0465","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.24395","article-title":"Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice","volume":"54","author":"Bansal","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0470","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0475","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00441-016-2407-9","article-title":"Alphav integrins: key regulators of tissue fibrosis","volume":"365","author":"Conroy","year":"2016","journal-title":"Cell Tissue Res."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0480","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1096-9896(199703)181:3<330::AID-PATH765>3.0.CO;2-7","article-title":"Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver","volume":"181","author":"Le Bail","year":"1997","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0485","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/gast.1996.v110.pm8613002","article-title":"Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells","volume":"110","author":"Carloni","year":"1996","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0490","first-page":"738","article-title":"Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver","volume":"143","author":"Couvelard","year":"1993","journal-title":"Am. J. Pathol."},{"issue":"16","key":"10.1016\/j.matbio.2018.04.006_bb0495","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1021\/jm020033k","article-title":"Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents","volume":"45","author":"Dubree","year":"2002","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0500","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1582-4934.2010.01072.x","article-title":"Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor (CCN2)","volume":"15","author":"Huang","year":"2011","journal-title":"J. Cell. Mol. Med."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0505","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9440(10)65005-5","article-title":"Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin","volume":"156","author":"Kim","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0510","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/excr.1996.0130","article-title":"Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation","volume":"224","author":"O'Brien","year":"1996","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0515","doi-asserted-by":"crossref","first-page":"G425","DOI":"10.1152\/ajpgi.00050.2011","article-title":"Role of integrins in fibrosing liver diseases","volume":"301","author":"Patsenker","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0520","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J. Hepatol."},{"issue":"49","key":"10.1016\/j.matbio.2018.04.006_bb0525","doi-asserted-by":"crossref","first-page":"30911","DOI":"10.1074\/jbc.272.49.30911","article-title":"The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture","volume":"272","author":"Racine-Samson","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"288","key":"10.1016\/j.matbio.2018.04.006_bb0530","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5094","article-title":"The alphavbeta1 integrin plays a critical in vivo role in tissue fibrosis","volume":"7","author":"Reed","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0535","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0046-8177(97)90250-1","article-title":"Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma","volume":"28","author":"Torimura","year":"1997","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0540","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0002-9440(10)65066-3","article-title":"Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis","volume":"156","author":"Levine","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0545","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/path.964","article-title":"Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C","volume":"195","author":"Nejjari","year":"2001","journal-title":"J. Pathol."},{"issue":"23","key":"10.1016\/j.matbio.2018.04.006_bb0550","first-page":"8312","article-title":"Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment","volume":"63","author":"Yang","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150567","article-title":"Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer","volume":"11","author":"Howe","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.matbio.2018.04.006_bb0560","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of alpha integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.matbio.2018.04.006_bb0565","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1681\/ASN.2015050585","article-title":"Pharmacologic blockade of alphavbeta1 integrin ameliorates renal failure and fibrosis in vivo","volume":"28","author":"Chang","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7474","key":"10.1016\/j.matbio.2018.04.006_bb0570","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","article-title":"Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma","volume":"503","author":"Gerber","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.matbio.2018.04.006_bb0575","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00535-016-1206-0","article-title":"Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via alphav integrin interaction","volume":"51","author":"Sugiyama","year":"2016","journal-title":"J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0580","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/hep.23144","article-title":"Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis","volume":"50","author":"Patsenker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.matbio.2018.04.006_bb0585","article-title":"Interaction of Src and alpha-V integrin regulates fibroblast migration and modulates lung fibrosis in a preclinical model of lung fibrosis","volume":"7","author":"Lu","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.matbio.2018.04.006_bb0590","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1172\/JCI40053","article-title":"Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages","volume":"119","author":"Atabai","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0595","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.28274","article-title":"Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis","volume":"63","author":"Peng","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0600","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","article-title":"Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression","volume":"135","author":"Patsenker","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0605","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","article-title":"Role of alphavbeta6 integrin in acute biliary fibrosis","volume":"46","author":"Wang","year":"2007","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.matbio.2018.04.006_bb0610","first-page":"L726","article-title":"Inhibition of the alphavbeta6 integrin leads to limited alteration of TGF-alpha-induced pulmonary fibrosis","volume":"306","author":"Madala","year":"2014","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0615","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","article-title":"Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation","volume":"177","author":"Horan","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0620","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2353\/ajpath.2007.060158","article-title":"Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse","volume":"170","author":"Hahm","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0625","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0002-9440(10)63486-4","article-title":"Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(\u2212\/\u2212) mice","volume":"163","author":"Ma","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.matbio.2018.04.006_bb0630","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1172\/JCI45589","article-title":"Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin alphavbeta8-mediated activation of TGF-beta","volume":"121","author":"Kitamura","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"241","key":"10.1016\/j.matbio.2018.04.006_bb0635","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008074","article-title":"Selective targeting of TGF-beta activation to treat fibroinflammatory airway disease","volume":"6","author":"Minagawa","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0640","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yjmcc.2008.10.022","article-title":"Cardiac myofibroblast differentiation is attenuated by alpha(3) integrin blockade: potential role in post-MI remodeling","volume":"46","author":"Bryant","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0645","first-page":"213","article-title":"Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis","volume":"119","author":"Kim","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2018.04.006_bb0650","article-title":"Mechanosensing by the alpha6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.matbio.2018.04.006_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12502","article-title":"PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis","volume":"7","author":"Martin","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150471","article-title":"Alpha8 integrin (Itga8) Signalling attenuates chronic renal interstitial fibrosis by reducing fibroblast activation, not by interfering with regulation of cell turnover","volume":"11","author":"Marek","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.matbio.2018.04.006_bb0665","doi-asserted-by":"crossref","first-page":"H96","DOI":"10.1152\/ajpheart.00918.2015","article-title":"The alpha11 integrin mediates fibroblast-extracellular matrix-cardiomyocyte interactions in health and disease","volume":"311","author":"Civitarese","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0670","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.2353\/ajpath.2009.090393","article-title":"Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders","volume":"175","author":"Nishimura","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"8\u20139","key":"10.1016\/j.matbio.2018.04.006_bb0675","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejcb.2008.01.012","article-title":"Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship","volume":"87","author":"Wipff","year":"2008","journal-title":"Eur. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0680","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.drudis.2014.09.025","article-title":"Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery","volume":"20","author":"Kothiwale","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.matbio.2018.04.006_bb0685","first-page":"55","article-title":"Discoidin domain receptors: potential actors and targets in cancer","volume":"7","author":"Rammal","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0690","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000479119","article-title":"The role of discoidin domain receptor 1 in inflammation, fibrosis and renal disease","volume":"137","author":"Dorison","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.matbio.2018.04.006_bb0695","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.matbio.2016.11.009","article-title":"Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis","volume":"57-58","author":"Borza","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19336918.2018.1448353","article-title":"Mechanical signaling through the discoidin domain receptor 1 plays a central role in tissue fibrosis","author":"Coelho","year":"2018","journal-title":"Cell Adhes. Migr."},{"issue":"8","key":"10.1016\/j.matbio.2018.04.006_bb0705","first-page":"207","article-title":"The effect of suppressing discoidin domain receptor expression on keloid formation and proliferation","volume":"21","author":"Jiang","year":"2009","journal-title":"Wounds"},{"issue":"7","key":"10.1016\/j.matbio.2018.04.006_bb0710","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.celrep.2017.01.061","article-title":"Discoidin domain receptor 1 mediates myosin-dependent collagen contraction","volume":"18","author":"Coelho","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.matbio.2018.04.006_bb0715","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.matbio.2013.12.002","article-title":"Discoidin domain receptors in disease","volume":"34","author":"Borza","year":"2014","journal-title":"Matrix Biol."},{"issue":"12","key":"10.1016\/j.matbio.2018.04.006_bb0720","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1681\/ASN.2006060677","article-title":"Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease","volume":"17","author":"Flamant","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.matbio.2018.04.006_bb0725","doi-asserted-by":"crossref","DOI":"10.1038\/srep21262","article-title":"Protective effects of genetic inhibition of Discoidin domain receptor 1 in experimental renal disease","volume":"6","author":"Kerroch","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.matbio.2018.04.006_bb0730","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.200603-333OC","article-title":"Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis","volume":"174","author":"Avivi-Green","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.matbio.2018.04.006_bb0735","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1021\/acs.jmedchem.6b00140","article-title":"Structure-based Design of Tetrahydroisoquinoline-7-carboxamides as selective Discoidin domain receptor 1 (DDR1) inhibitors","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0740","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ajpath.2010.11.068","article-title":"Discoidin domain receptor 1: isoform expression and potential functions in cirrhotic human liver","volume":"178","author":"Song","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.matbio.2018.04.006_bb0745","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI200112373","article-title":"DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells","volume":"108","author":"Olaso","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0750","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1016\/j.ajpath.2011.09.002","article-title":"Loss of discoidin domain receptor 2 promotes hepatic fibrosis after chronic carbon tetrachloride through altered paracrine interactions between hepatic stellate cells and liver-associated macrophages","volume":"179","author":"Olaso","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0755","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gutjnl-2011-300810","article-title":"Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis","volume":"61","author":"Badiola","year":"2012","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0760","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/mt.2016.109","article-title":"Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis","volume":"24","author":"Zhao","year":"2016","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.matbio.2018.04.006_bb0765","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbamem.2016.05.001","article-title":"A specific, transmembrane interface regulates fibroblast activation protein (FAP) homodimerization, trafficking and exopeptidase activity","volume":"1858","author":"Wonganu","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.matbio.2018.04.006_bb0770","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/14728222.2017.1370455","article-title":"Fibroblast activation protein-alpha in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?","volume":"21","author":"Juillerat-Jeanneret","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5\u20136","key":"10.1016\/j.matbio.2018.04.006_bb0775","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin. Appl."},{"issue":"3","key":"10.1016\/j.matbio.2018.04.006_bb0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150287","article-title":"Cleavage of type I collagen by fibroblast activation protein-alpha enhances class A scavenger receptor mediated macrophage adhesion","volume":"11","author":"Mazur","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0785","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1034\/j.1600-0676.2002.01503.x","article-title":"Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection","volume":"22","author":"Levy","year":"2002","journal-title":"Liver"},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0790","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.matbio.2018.04.006_bb0795","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1074\/jbc.M115.701433","article-title":"Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice","volume":"291","author":"Fan","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.matbio.2018.04.006_bb0800","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ibd\/izx008","article-title":"Inhibition of fibroblast activation protein restores a balanced extracellular matrix and reduces fibrosis in Crohn's disease strictures ex vivo","volume":"24","author":"Truffi","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.matbio.2018.04.006_bb0805","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","article-title":"Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis","volume":"809","author":"Egger","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.matbio.2018.04.006_bb0810","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clon.2009.04.007","article-title":"Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer","volume":"21","author":"Eager","year":"2009","journal-title":"Clin. Oncol."},{"issue":"5","key":"10.1016\/j.matbio.2018.04.006_bb0815","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.matbio.2018.04.006_bb0820","first-page":"2296","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Matrix Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X18301604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X18301604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:14:31Z","timestamp":1751559271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0945053X18301604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":164,"alternative-id":["S0945053X18301604"],"URL":"https:\/\/doi.org\/10.1016\/j.matbio.2018.04.006","relation":{},"ISSN":["0945-053X"],"issn-type":[{"value":"0945-053X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver fibrosis: Direct antifibrotic agents and targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Matrix Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.matbio.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}